drugset / Trial / NCT01563055

A Phase I/II, Open-label Study of Ofatumumab Added to Chlorambucil in Previously Untreated Japanese Patients With Chronic Lymphocytic Leukemia

NCT01563055

Phase 2 Completed 10 enrolled GlaxoSmithKline
NaSingle-groupOpen-labelTreatment

Summary

This is an open-label study to evaluate tolerability, safety, efficacy and pharmacokinetic profile of ofatumumab in combination with chlorambucil in Japanese patients with previously untreated Chronic Lymphocytic Leukemia (CLL).

Timeline

Start
2012-04
Primary completion
2014-11
Completion
2014-11

Drugs

EvaluationDrugModalityDoseRoute
Subject Chlorambucil Other / unclassified 10 mg/m2 Oral
Subject Ofatumumab Monoclonal antibody 1000 mg Intravenous